Market Place
Sourcing Support
Matica Bio And CytoImmune Partner On Cell Therapy Program
10 Oct 2024 //
CONTRACTPHARMA
CytoImmune to Present Preclinical Data Highlighting Potential of TRACK-NK Cells
10 Nov 2022 //
BUSINESSWIRE
CytoImmune Therapeutics Appoints Remus Vezan as Chief Medical Officer
07 Sep 2022 //
BUSINESSWIRE
CytoImmune and City of Hope Begin Dosing in PI Trial Evaluating NKCT
28 Jul 2022 //
BUSINESSWIRE
CytoImmune Presents Data on NK Cell-Based Therapies for Hematology & Solid Tumor
11 Apr 2022 //
BUSINESSWIRE
CytoImmune to Participate in Upcoming April Investor Conferences
07 Apr 2022 //
BUSINESSWIRE
CytoImmune Tx Opens Company’s Clinical Cell Manufacturing Facility in Toa Baja
24 Mar 2022 //
BUSINESSWIRE
CytoImmune to Present New Preclinical Data on TRACK-NK Cell Therapies
08 Mar 2022 //
BUSINESSWIRE
CytoImmune CEO breaks down her 3 `pillars` of success; Novartis, and more
12 Nov 2021 //
ENDPTS
CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer
26 Jun 2021 //
PR NEWSWIRE
CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer
26 Jun 2021 //
PR NEWSWIRE
CytoImmune Therapeutics Welcomes Aleksey Krylov, Chief Financial Officer
26 Jun 2021 //
PR NEWSWIRE
City of Hope Enters Licensing Agreements with CytoImmune Therapeutics
08 Apr 2021 //
BUSINESSWIRE
CytoImmune Establishes Operations in Puerto Rico to Develop Novel Cancer
01 Mar 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.